A body image scale for use with cancer patients
A body image scale for use with cancer patients
复制标题
DOI：
10.1016/s0959-8049(00)00353-1
复制
发表时间：
2001-01-01
影响因子：
8.4
通讯作者：
Ghazal, SA
中科院分区：
文献类型：
--
作者：
Hopwood, P;Fletcher, I;Ghazal, SA
身体形象是生活质量评估的一个重要终点，因为癌症治疗可能会因手术毁容、放射治疗的后期影响或全身治疗的不良反应而导致患者外观发生重大变化。确定需要开发一种用于临床试验的短身体图像恐慌 (BIS)。与欧洲癌症研究与治疗组织 (EORTC) 生活质量研究小组合作构建了包含 10 项的量表，并在 276 名英国癌症患者的异质样本中进行了测试。修订后，该量表使用来自七项英国治疗试验/临床研究的数据集对 682 名乳腺癌患者进行了心理测量测试。该量表显示出高可靠性（Cronbach's alpha 0.93）和良好的临床效度，基于反应率、判别效度（P < 0.0001，Mann-Whitney 检验）、变化敏感性（P < 0.001，Wilcoxon 符号秩检验）以及不同乳腺癌治疗中心评分的一致性。因子分析在四分之三的分析中得出单因子解决方案，占 > 50% 的方差。这些结果支持 BIS 作为评估癌症患者身体形象变化的简短调查问卷的临床有效性，适合在临床试验中使用。 (C) 2001 Elsevier Science Ltd. 保留所有权利。
Body image is an important endpoint in quality of life evaluation since cancer treatment may result in major changes to patients' appearance from disfiguring surgery, late effects of radiotherapy or adverse effects of systemic treatment. A need was identified to develop a short body image scare (BIS) for use in clinical trials. A 10-item scale was constructed in collaboration with the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Study Group and tested in a heterogeneous sample of 276 British cancer patients. Following revisions, the scale underwent psychometric testing in 682 patients with breast cancer, using datasets from seven UK treatment trials/clinical studies. The scale showed high reliability (Cronbach's alpha 0.93) and good clinical validity based on response prevalence, discriminant validity (P < 0.0001, Mann-Whitney test), sensitivity to change (P < 0.001, Wilcoxon signed ranks test) and consistency of scores from different breast cancer treatment centres. Factor analysis resulted in a single factor solution in three out of four analyses, accounting for > 50% variance. These results support the clinical validity of the BIS as a brief questionnaire for assessing body image changes in patients with cancer, suitable for use in clinical trials. (C) 2001 Elsevier Science Ltd. All rights reserved.